Exosome Drug Developer Capricor Therapeutics Inc (CAPR) is Initiated by ROTH Capital to Buy

from The Market Digest by Robert Westfall

Capricor Therapeutics Inc (CAPR) was Initiated by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Jun 15, 2016.

Capricor Therapeutics Inc opened for trading at $3.31 and hit $3.54 on the upside on Tuesday, eventually ending the session at $3.54, with a gain of 3.81% or 0.13 points. The heightened volatility saw the trading volume jump to 21,499 shares. Company has a market cap of $64 M.

Capricor Therapeutics Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development which include CAP-1002 CAP-1001 CSps Exosomes Cenderitide (CD-NP) and CU-NP. The Company’s technology is based in cardiospheres (CSps) which are multi-cell clusters of cardiac derived cells. The Company’s product candidate the cardiosphere-derived cells (CDC) is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).

exosome rna

Source – The Market Digest

Leave a Reply

Your email address will not be published. Required fields are marked *